Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation
Status:
Terminated
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
This is an open-label analysis that will compare eculizumab versus Plasmapheresis (PP) and
Immunoglobulin (IVIg) for the treatment of antibody-mediated rejection (AMR) in renal
transplant recipients. All patients will be evaluated from the time of AMR diagnosis for 12
months.